LUX-Lung 7 Trial Demonstrates Efficacy of Afatinib Over Gefitinib
Second-generation, EGFR-directed therapy afatinib (Gilotrif) may be superior to first-generation gefitinib (Iressa) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive, advanced non-small cell lung cancer.
Second-generation, EGFR-directed therapy afatinib (Gilotrif) may be superior to first-generation gefitinib (Iressa) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive, advanced non-small cell lung cancer (NSCLC), according to new results from the
The results, which were presented January 27, 2016, at the 14th Annual British Thoracic Oncology Group (BTOG)
The researchers reported that significantly more patients had an objective tumor response with afatinib when compared to gefitinib (70% versus 56%), with a median duration of response of 10.1 months for afatinib and 8.4 months for gefitinib. The improvement in PFS with afatinib was consistent across most predefined clinical subgroups, including gender, age, race, and EGFR mutation type.
“As the first global head-to-head trial directly comparing two EGFR-directed therapies for the treatment of patients with EGFR mutation-positive NSCLC, LUX-Lung 7 marks a significant milestone to better understanding the benefits of first-line treatment options for this population,” said Shirish Gadgeel, MD, who is the leader of the Thoracic Oncology Multidisciplinary Team and president of the Medical Executive Committee of the Karmanos Cancer Center, Detroit, in a
The phase IIb trial included 319 patients with advanced stage NSCLC harboring common EGFR mutations (del19 or L858R) who received no prior treatment. The study showed that the overall frequency of patients experiencing serious adverse events and discontinuing treatment due to adverse events was similar in both arms.
Treatment with both afatinib and gefitinib in the LUX-Lung 7 trial was generally tolerable, leading to an equally low rate of treatment-related discontinuation in both arms (6.3%). The most common grade ≥3 related AEs with afatinib were diarrhea (12.5%) and rash/acne (9.4%). The most common grade ≥3 related AEs with gefitinib was AST/ALT increase (8.8%) and rash/acne (3.1%). Drug-related interstitial lung disease was reported in four patients on gefitinib and no patients on afatinib.
“Interestingly, the progression-free survival difference observed in the LUX-Lung 7 trial became more prominent over time so that the progression-free survival rate was more than doubled with afatinib at 24 months,” said Mehdi Shahidi, MD, Medical Head, Solid Tumor Oncology, Boehringer Ingelheim.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025